TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Area under the curve from time zero to infinity (AUC0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of maculopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for laser treatment for maculopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recommendation of psychotherapeutic treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Induction to complete abortion interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients discharged by 0900h
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Vascular events rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Bleeding mortality
Endpoint domain: Mortality/survival
Primary endpoint: mortality at one year
Endpoint domain: Mortality/survival
Primary endpoint: Thermal sensation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of antibiotic therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hypercalcemia
Endpoint domain: Adverse events/effects
Primary endpoint: adverse events including respiratory depression
Endpoint domain: Adverse events/effects
Primary endpoint: Glycemic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulinemic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Solicited local adverse reactions (ARs) incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Volume of in-stent neointimal hyperplasia (NIH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neointima hyperplasia progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: myodynamia of upper limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: myodynamia of hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: total scores of nervous dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: TBS change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported appetite scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: self-efficacy ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: post-intervention OSCE score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of intubation (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety levels in patients with PTSD
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Brain metabolic response to yohimbine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: anterior lens capsule stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal respiratory pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: thoracic expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: abdominal mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perioperative or postoperative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Severe GFR impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: venous thromboembolism and death from all causes
Endpoint domain: Mortality/survival
Primary endpoint: Transforming growth factor‐beta levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokine gene expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of body pain sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean load to fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper limb pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systematic motor function of the upper limbs improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nailfold microcirculation improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic blood pressure (SBP) recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dust loadings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alfentanil consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores on admission
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: End-diastolic LV diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: End-systolic LV diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mortality prediction for heart attack or stroke patients
Endpoint domain: Mortality/survival
Primary endpoint: collagen synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular hospitalizations or death events
Endpoint domain: Mortality/survival
Primary endpoint: Mean total cost incurred
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: accuracy rate of knee joint injections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Documentation of timely cholesterol screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Up-to-date Papanicolaou smear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of hospital admissions per patient
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Six Minute Walk Distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total SGRQ Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Net cost per QALY gained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 12-week abstinence rates
Endpoint domain: Mortality/survival
Primary endpoint: mean utility
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: societal cost per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: tumor stabilization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of daytime consultations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Tn I release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of arrhythmias
Endpoint domain: Adverse events/effects
Primary endpoint: L* value improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Melanin index (M.I.) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: quasi L* value improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement of process quality
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Proportion of time >or= 140 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of time <or= 70 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Spontaneous deliveries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Instrumental deliveries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Augmentation start to delivery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Cure or improvement in treated women
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure or improvement in treated men
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of vital bone (VB%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of residual bone materials (RBM%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of connective tissue/marrow (CT%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insomnia reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological wellbeing improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Efficiency measured as time used to pass the scenario
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction measured by a questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: nurse and patient satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mobility and comfort
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: EFM positioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement in sexual arousal
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in MCP‐1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in IL‐8 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Children's postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to recommended follow-up timing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial blood pressure (BP) and heart rate (HR) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative agitation
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative lethargy
Endpoint domain: Adverse events/effects
Primary endpoint: Intraocular Pressure (IOP) lowering effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of inflammatory reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum CTX level decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: loss of lean body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: CFF reduction alleviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ocular fatigue sensation mitigation
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: mean gain of clinical attachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in probing depth (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of sites with PD5 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target discrimination performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: femoral head viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Decline
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Nocturnal hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Glycaemic control (HbA1c change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Annual cost incurred
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence to anti-psychotic medication
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of ankle sprains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Magnesium balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum magnesium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Red blood cell magnesium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proximal migration of the LES
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time spent below a pH of 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Development of dry eye
Endpoint domain: Adverse events/effects
Primary endpoint: Systemic exposure (plasma concentration profile, AUC, Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: force accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: sensitivity of OCT in normal segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specificity of OCT in normal segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-Free Survival (PFS) at 9 months
Endpoint domain: Mortality/survival
Primary endpoint: disease-specific death
Endpoint domain: Mortality/survival
Primary endpoint: ankle dorsiflexion improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased spasticity trend
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of DAA in severe sepsis
Endpoint domain: Mortality/survival
Primary endpoint: lower alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in health status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LKES score difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: POSE Score difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DPI improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MCQ total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ST segment resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of deterioration to chronic severe hepatitis
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of complications (gastrointestinal bleeding, infections, hepatic coma, kidney failure)
Endpoint domain: Adverse events/effects
Primary endpoint: Recovery of liver function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: OCD symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed LLL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal bone changes in the symphysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: decrease in tHcy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endoscopic disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Stent lumen cross-sectional area (CSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal luminal diameter (MLD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS ratings of stimulated, happy, talkative, open, and want to be with others
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recognition of happy faces on the FERT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional empathy for positive stimuli on the MET
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall AMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Dosing error rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Large overdosing error rate
Endpoint domain: Adverse events/effects
Primary endpoint: total effective rate after two courses of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: norepinephrine requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma concentration of C3a
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma concentration of C5a
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Disease-free survival (DFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Nocturnal hypoglycaemia rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum PTH concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in paraspinal CT measurements at L5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feelings of elation and energy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: feelings of confusion and anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: increased sedation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Image quality for small-caliber vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast agent dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mRNA expression level of FAF-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: protein expression levels of IL-8, MCP-1, and GRO-α
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: protein expression level of COX-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HCW tolerance for product C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Movement from disordered to normal range on the CES-D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum fructosamine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fixation stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in VAS scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in QLQ scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Decrease in Eosinophils in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quality of daily life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Glucose-stimulated maximum increase in plasma insulin immunoreactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: PVT-B performance post-nap
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DSST performance post-nap
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-rated performance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Levels of ACTH during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Levels of beta-endorphin during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Vaccine efficacy against severe rotavirus gastroenteritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Seroconversion rate after second dose of RIX4414
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Relief of vaginal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in epithelial atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased vaginal maturation values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of dying from prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: Mean overall quality score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Plasma vitamin C concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxalate excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: leisure walking increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes